Liu et al., 2021 - Google Patents

Design, synthesis, and Biological evaluation of APN and AKT Dual-Target inhibitors

Liu et al., 2021

View HTML
Document ID
646085502860087661
Author
Liu Q
Dong H
Zhao W
Zhang G
Li S
Xu Q
Zhang Y
Publication year
Publication venue
ACS Medicinal Chemistry Letters

External Links

Snippet

Herein a novel series of APN and AKT dual inhibitors were derived from the clinical AKT inhibitor AZD5363. It was demonstrated that most compounds exhibited remarkable APN inhibitory activities with the most potent compound 8b (IC50= 0.05±0.01 μM) being over 70 …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Yuan et al. Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application
Wang et al. Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein
Luan et al. Kinase and histone deacetylase hybrid inhibitors for cancer therapy
Hu et al. In situ “click” assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups
Tsai et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Kim et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor
Chen et al. Dual NAMPT/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery
Zhu et al. 2-Amino-2, 3-dihydro-1 H-indene-5-carboxamide-based discoidin domain receptor 1 (DDR1) inhibitors: design, synthesis, and in vivo antipancreatic cancer efficacy
Daniele et al. Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells
Komachi et al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo
Tavares et al. Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models
Huang et al. Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors
Ni et al. Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1
Mehta et al. Complex roles of discoidin domain receptor tyrosine kinases in cancer
He et al. Discovery of the first potent IDO1/IDO2 dual inhibitors: a promising strategy for cancer immunotherapy
Zheng et al. Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies
Nema et al. Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma
Xu et al. Discovery of isoform-selective Akt3 degraders overcoming osimertinib-induced resistance in non-small cell lung cancer cells
Quan et al. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer
Sibley et al. Discovery of a small side cavity in sphingosine kinase 2 that enhances inhibitor potency and selectivity
Shillingford et al. Mitogen-activated protein kinase phosphatases: No longer undruggable?
Davis-Gilbert et al. Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2
Zhang et al. Design, synthesis, and biological evaluation of 2-formyl tetrahydronaphthyridine urea derivatives as new selective covalently reversible FGFR4 inhibitors
Singh et al. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022
O'Neill et al. Function and targeting of MALT1 paracaspase in cancer